Colon Cancer and Colorectal Cancer Treatment Options with Powerful Combinations Designed for a Holistic Recovery

Living a long, healthy, and cancer-free life is possible, despite facing a late-stage or metastatic colon cancer diagnosis. At Envita Medical Centers, a world-class integrative center for Precision Oncology, we have been treating complex and late-stage cancers for over 25 years by combining the best in conventional medicine with advanced natural therapies. The goal of team Envita is to pursue lasting progress in the fight against colorectal cancer, a term used to define cancers of the colon and rectum regions, and survivors like Sandy Y. bear testimony to our relentless endeavors.

Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.

Most cancer hospitals in the country follow the NCCN (National Comprehensive Cancer Network) guidelines, which does not give them the liberty to deviate much from a set protocol and personalize treatment based on each patient’s unique biomarkers. Biomarkers refer to the proteins, genes, and other molecules which affect your distinctive colon cancer’s growth and metastatic spread. This constraint in the one-size-fits-all regimens deprive patients of a true second opinion, which Sandy finally received at Envita, and feels fortunate about getting treated in time for her aggressive stage IV colon cancer.

Sandy came to us 25 years ago with Metastatic Colon Cancer, after facing bleak prognoses from some of the renowned cancer hospitals in the nation.

Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.

According to the American Cancer Society, which relies on data compiled and maintained by the National Cancer Institute (NCI), the 5-year relative survival rate for colon cancer is a dismal 14% when the disease has metastasized to distant parts of the body.

However, Sandy has defied these statistics with our unique cancer care approach, and her enthusiasm in sharing her journey from being a colon cancer patient to cancer-free for decades speaks volumes about our powerful combinations of leading edge conventional and advanced natural therapies. The medical technology we provide at Envita today is light years ahead of what we could offer Sandy 25 years ago, which proves our dedication towards innovating in the field of personalized precision oncology to help every patient overcome their disease.

How Does Personalized Precision Oncology Help in Your Holistic Recovery?

Personalized precision oncology goes beyond the standardized treatment of colon cancer to identify, the drivers of genomic alterations, biomarkers, and immune dysfunction. All these causative factors are unique to each individual colon cancer patient, which is why a personalized approach is needed to address and treat the root cause of each individual patient’s unique cancer.
Dr. Dino Prato NMD
Founder/CEO Envita Medical Centers

Personalization to Tackle Colorectal Cancer Recurrence

Our customized treatment plans are aimed at precision-targeting the distinctive colon (colorectal) cancer expressions of each patient to give them the best chance to respond to care. At Envita, we excel in personalizing each colorectal cancer patient’s treatments with the latest medical innovations while rebuilding their immune system, which is essential for a long-term remission, unhindered by recurrences.

Detailed Case Study Showing Remarkable Improvements With Precision Oncology in a Stage 4 Colorectal Cancer Patient

Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.

At Envita, we understand the importance of going beyond stipulated NCCN guidelines to chart a unique medical blueprint, which may help in overcoming the challenges of recurrence and metastases. The following are some of the hurdles in colorectal cancer treatments, which we aim to overcome with our custom-developed advanced precision oncology protocols:

  • The standard NCCN guided treatments based on cancer type and stage may not be enough to check recurrence, which is one of the most important factors influencing survival of colorectal cancer patients [1].
  • According to recent medical research, colorectal cancer can spread very soon after the original polyp or tumor has developed, maybe years before the disease is diagnosed [2].
  • With standard chemotherapy the 5-year relative survival rate of metastatic colon cancer is as low as 10 percent [3].

At Envita, we understand the importance of going beyond stipulated NCCN guidelines to chart a unique medical blueprint, which may help in overcoming the challenges of recurrence and metastases.

What is Metastatic Colorectal Cancer?

Metastasis refers to the spread of cancer beyond its primary site of origin. For instance, a cancer originating in the colon or the rectum, can spread or metastasize to the nearby lymph nodes and gradually affect distant regions such as the lungs, liver, brain, or bones.

Metastasis from the primary site of cancer can begin even when the polyp or tumor size is as small as 2mm in diameter, often the size seen in early stage II or stage I fully contained tumors. Tiny micro-metastatic cancer cells break away from a growing tumor and travel through blood vessels, seeding the disease at different regions or organs.

At Envita, we have several proprietary treatments beyond standard healthcare options like radiofrequency ablations and hepatic arterial infusions to address liver metastases or other sites of colorectal cancer spread, such as lungs, bones, or any other organs.

Learn more about Metastasis

Envita Medical Centers
Medical Team

Physicians with MD, NMD, DO, DO(h), MD(h), medical licenses
22
Pharmacists specializing in integrative agents
7
Nurses trained in precision treatment delivery
40+

Envita’s Precision Oncology May Improve Outcomes and Save Lives

At Envita, we see many patients with cancer recurrence or metastasis, despite receiving standard NCCN guideline treatments and participating in clinical trials. In our clinical opinion, the lack of personalization to genetically target each patient’s unique cancer expressions, in both these treatment approaches leads to advanced colon cancer that metastasizes to different parts of the body.

The one-size-fits-all NCCN guidelines are based on clinical trial data, ignoring each patient’s individual cancer expressions, which is why not all patients with the same stage and type of colon cancer respond similarly to the same treatment. These guidelines don’t allow access to precision oncology, until patients fail initial first-line treatments based on cancer type and stage. The delay in access to precision care may turn catastrophic for certain patients.

On the contrary, every patient at Envita begins treatment with our uniquely detailed Precision Oncology Algorithms.

Envita Medical Centers building

Less than 20% of all cancer patients get access to precision oncology [4] and even when they do, they get a watered-down version of Envita’s detailed precision algorithms. Our level of precision is much more in-depth, and includes testing of several other parameters, which play a direct or indirect role in cancer growth, recurrence, and metastasis.

Envita’s Precision Algorithm identifies each patient’s unique Colorectal Cancer drivers, paving the way to longer disease-free survival!

Envita Precision Algorithm vs.
Standard Oncology Precision Testing

RNA Transcriptome Genes
Envita Medical Centers: 20,000+
Standard Oncology: Unchecked
SNV/CNV Genes
Envita Medical Centers: 452
Standard Oncology: 309
Rearrangements/Fusion Genes
Envita Medical Centers: 51
Standard Oncology: 27
Microsatellite Instability (MSI)
Envita Medical Centers: Checked
Standard Oncology: Checked
Tumor Mutation Burden (TMB)
Envita Medical Centers: Checked
Standard Oncology: Checked
BRCA 1/2
Envita Medical Centers: Checked
Standard Oncology: Checked
Immunohistochemistry
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Chemosensitivity
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Concurrent Liquid Biopsy
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Exosomal miRNA Analysis
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Circulating Tumor Cells Enumeration
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Pharmacogenomics
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Individualized Therapy Recommendation
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Carcinogenic Exposure - Root Causes
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Inflammation Markers
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Metabolic Target Drivers
Envita Medical Centers: Checked
Standard Oncology: Unchecked

*Individual results may vary. Envita makes no guarantees for outcomes.

Envita’s detailed precision algorithm offers a better understanding of the unique ecosystem of each patient’s distinctive cancer, which is crucial to customize treatment for reducing chances of drug resistance. Chemotherapeutic drug resistance is a challenge in cancer treatment because it may render treatment ineffective, causing disease complications and metastasis. Given that the drug resistance mechanisms are different among colon cancer patients and may change even in a single patient at different stages, personalized and specific combination therapy is proposed to be more effective and safer for the reversal of drug resistance [5], which is what we follow here at Envita, leading to numerous successful recoveries like Sandy.

Learn more about Chemotherapeutic Drug Resistance

Unique and Advanced Treatments for Colon Cancer and Colorectal Cancer

At Envita Medical Centers, we find that majority of our patients were on the wrong drug targets before coming to us and in our clinical experience, nearly all patients are missing vitally important targets to their cancer treatment. When targeting is missed due to the absence of detailed genomic testing, patients lack actionable metastatic disease information, which is needed to guide the treatment in real-time.

Many colon (colorectal) cancer patients perusing standard cancer treatment may have to undergo a colectomy, surgical removal of colon, and have to use a colostomy bag to divert solid waste out of their body, but our treatments attack your cancer while healing you holistically. At Envita, with our personalized precision options we aim to ensure that surgical resections, if any, do not impact your quality of life, as we work towards increasing longevity and reducing toxicity in your body, just like in Sandy’s case.

Adjuvants
Sandy was given only 20% - 30% chance of survival beyond a year, despite going through standard NCCN guideline treatments. However, with Envita's precision technology, she defied these statistics and has been leading a healthy and cancer free life for over two decades.

A genetic disease like cancer needs personalized treatment because genetics vary from person to person. We offer personalized genetically targeted treatment in a unique N of 1 model, enabling us to modify treatment based on individual patient responses. Our four-pillared approach to customize your treatment at every level helps in striking at the core of the disease, pushing you closer towards a long-term remission.

Graph depicting Envita Medical Centers' method

Step 1

Genomic Identification Increases Treatment Options

At Envita, we perform an extensive genomic identification to understand the root cause of each patient’s cancer expressions, irrespective of their colon cancer stages. This detailed testing helps us analyze many more mutations, beyond epidermal growth factor receptor (EGFR), neurotrophic tropomyosin receptor kinases (NTRK), microsatellite instability (MSI), BRAF, and RAS family of genes. According to the National Cancer Institute, 45% of colorectal cancers are driven by the RAS family of genes.

At Envita, we understand that approximately 5 percent of all colon cancers may be the result of mutations due to inherited causes, leaving the remaining 95 percent to other factors such as diet, environment, heavy metal exposure, chemical toxins, and infections [6]. Findings from extensive epidemiological and experimental investigation have linked consumption of several foods and nutrients to the risk of colorectal neoplasia [7].

All these factors may trigger genetic mutations, which can evade the immune system, leading to the growth of cancer. Decoding the cause and the specific genetic mutations, in each individual patient is a crucial step to treating this genetic disease.

Step 2

Immuno Targeting Trains Your Body to Attack the Cancer

At Envita, we use the Ultra Analytes Liquid Biopsy to examine genetic mutations and establish actionable chemo and immunotherapy targets. These targets are deciphered from a detailed analysis of the Circulating Tumor Cells (CTCs) in a patient’s blood sample. CTCs are small particles which break away from a growing polyp or tumor and enter the patient’s blood stream, carrying the cancer in micro metastatic forms to other parts of the body.

There are many advantages of analyzing the CTCs via liquid biopsy, over the standard healthcare approach involving invasive tumor biopsies. Most hospitals do a tissue biopsy during initial cancer diagnosis and basing your treatment on this biopsy may not be effective, because the fast-mutating cancer cells can change biomarker information quickly. On the contrary, investigating the CTCs enables our treatment to constantly evolve and stay ahead of the mutations, allowing even late-stage patients like Sandy to respond to care and recover holistically. In early-stage cancer cases, the liquid biopsy helps to identify and proactively treat sites of metastasis, even before the cancer manifests itself in distant parts.

Advanced Immunotherapy for Colon Cancer

Our personalized treatment protocols increase the mechanisms of action against each patient’s specific cancer by including customized immunotherapy options. Immunotherapy utilizes genetic information to assist the immune system in finding and killing cancerous cells. Our body is naturally adapted at killing thousands of cancerous and precancerous cells daily, but this ability may get impacted when your immune system is not performing optimally.

Standard healthcare treatments, such as maximum dose chemotherapy regimens, radiation therapy, and surgery may negatively impact patients’ immune systems. In certain cases, the extent of the impact is detrimental enough to severely depress the immune system, allowing the cancer to continue its spread. At Envita, we harness the power of immunotherapy to check this growth and proliferation.

With the advent of smart drugs, immunotherapy has become an integral part of colorectal cancer treatment. However, our immunotherapies go beyond the scope of smart drugs or checkpoint inhibitors available on the market, as we customize different therapies and drugs to optimize treatment efficacy for each individual patient.

Patients may not respond to prescribed smart drugs for colon (colorectal) cancer, if their immune system is acutely poor, which is why we empower their immune system cells, in particular the NK (natural killer) and dendritic cells. A reactivated immune system is then capable of executing the desired impact of the smart drugs and check disease proliferation.

Learn more about Immunotherapy

Step 3

Personalized Drug Design Enhances Treatment Efficacy

At Envita Medical Centers, we take personalization to the next level by designing patient-specific drugs to attack cancerous cells and improve overall gastrointestinal health. In our clinical opinion, a powerful combination of FDA approved drugs, repurposed drugs, and custom-compounded adjuvants improves your chances of overcoming the disease.

FDA Approved Drugs
Optimized for your cancer mutations.
Repurposed Drugs
Off-label use of approved medications
Custom Compounded Adjuvants
Genetically typed for each patient.

We take the guesswork out of your colorectal cancer treatment as our detailed testing reveals your specific biomarkers, which guide us to the FDA approved and repurposed drugs with the highest potential of impacting your cancer. We even adjust the doses of each of these drugs to suit the needs of the patient. Every patient metabolizes differently, making dosage adjustment critical to optimize medicine benefits and reduce its toxicity.

However, the FDA approved and repurposed drugs available on the market may not be effective against all the biomarkers, revealed through our exhaustive testing. To fill this gap, we custom compound adjuvants at our in-house pharmacy, which may help in debulking the tumor while strengthening your immune system.

Our custom compounded adjuvants include advanced phytotherapeutics, comprising plant extracts and herbs, which may prove to be most effective against each patient’s unique biomarkers. They may be used either as neoadjuvants (deployed before systemic therapies), adjuvant therapy (follow-up to systemic therapies), or as part of our proprietary systemic therapies as well.

Envita’s medicine combinations may be effective against unresectable cancers as they can cut off blood supply to tumors by impacting the production of vascular endothelial growth factor (vegf), a signal protein which stimulates the formation of blood vessels around tumors.

Step 4

Precision Deployment Offers New Treatments with Fewer Side Effects

We bring the benefits of new treatments from around the world to our patients, as we aim to reduce side effects and avoid invasive surgeries with our precision deployment. Polyps or tumors that cannot be removed via colonoscopy may be deactivated through our proprietary interventional radiology procedures, which kill the cancerous cells with minimal side effects.

Our proprietary methods of precision deployment increase the bio absorption of anti-cancer medicines and reduce their side effects. In certain cases, the side effects can be severe enough to demotivate patients from continuing treatment, which is what Sandy experienced with her one-size-fits-all conventional treatment.

To counter such challenges, at Envita we use intravenous or interventional radiology procedures, which administer the chemo and immuno agents directly at the cancer site, minimizing chances of damaging surrounding healthy cells. Depending on each patient’s biomarkers and the site and size of their colorectal polyps or tumors, our doctors decide on any one or a combination of precision deployment mechanisms to attack their cancer, while healing them holistically.

At Envita, we treat our patients like family while offering them all aspects of palliative care during treatment, as described by the American Cancer Society, except transitioning to hospice care because we do not take in patients if we cannot make a difference to their lives. We do a free medical records review for all patients before we decide to take them in for treatment. In fact, we have treated several patients who were sent to hospice care by conventional cancer treatment centers and today they are leading a healthy, disease-free life.

Here are some of our proprietary treatments:

GTFC™ (Genetically Targeted Fractionated Chemotherapy)

GTFC™ (Genetically Targeted Fractionated Chemotherapy), determines patient-specific chemotherapy options based on genetic testing and not primary cancer site alone. Cancers are caused by mutations occurring within cells, therefore selecting treatments based on genetic mutations can provide advantages that may have gone overlooked [8].

The knowledge of which chemotherapies and natural agents are likely to be most effective against each patient’s specific colorectal cancer biomarkers, allows us to utilize metronomic dosing, often 1/10 of the dose patients receive at regular cancer clinics. The low dose of chemotherapy enables us to use multiple targeted agents at once, with far less side effects as compared to maximum dose chemotherapy.

Many of our patients complain that the chemotherapies they received at their previous clinics were worse than the symptoms of cancer itself. At Envita, fewer side effects help our patients to sail through the treatment smoothly, as their immune system’s ability to check cancer growth and spread is improved through the treatment process.

Envita's GTFC™ vs.
Standard Chemotherapy

Helps to improve chemotherapy delivery to the tumor using a "Trojan Horse" delivery mechanism.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Uses genetic molecular profiling to understand all the facets of each patient's specific cancer.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Uses targeted treatment to enhance the mechanism of cancer kill.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Uses microdosed (fractionated) chemotherapies, reducing the chances of impacting healthy cells.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Minimizes toxicity to normal cells, lowering the chance of side-effects related to administration.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Uses patient-specific supportive immunotherapy to strengthen the immune system.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Aims to reduce multidrug resistance by administering 10 - 20% of the medication delivered in maximum dose chemo.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Allows custom-compounded medications to be readministered in tandem to suit each patient's individual cancer mutations.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked

*Individual results may vary. Envita makes no guarantees for outcomes.

Learn more about Genetically Targeted Fractionated Chemotherapy

CIPI™ (Chemo Immuno Precision Injections)

In certain cases of advanced colorectal cancer, patients may develop liver tumors, renal carcinomas, or tumors in other parts of the body as the cancer metastasizes. To treat these sites of metastases, we use CIPI™ (Chemo Immuno Precision Injections), a unique form of tumor chemoembolization for shutting off inoperable tumors that are fibrous and difficult to penetrate through traditional intravenous chemotherapy methods. This interventional radiology procedure has the potential to revolutionize the treatment of late-stage colorectal cancers by targeting large tumor sites of cancer metastasis.

With CIPI™, genetically personalized micro-dosed medications are directly injected into the tumor via a tiny catheter, thinner than a strand of hair. These medications deactivate the tumors, which then emit antigens, training your immune system to identify and kill cancer cells elsewhere in the body. This reactivated ability of the immune system helps in reducing chances of metastasis, stacking the odds in favor of the colon (colorectal) cancer patients.

Envita's CIPI™ vs.
Standard Surgery

Minimally invasive so it can be performed within 40-50 minutes, without the need for large surgical incisions.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Can be performed multiple times, even at close intervals, because there is minimal risk of post-op complications.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
No need for general anesthesia, reducing the health risks that can result from being put into a medically induced coma to perform an invasive surgery.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Faster recovery time as compared to traditional surgery, due to the minimally invasive administration.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Provides direct tumor targeting, which delivers patient-specific genomic agents into the tumor.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Causes a systemic immune response where the immune system is reactivated to find and attack other metastatic cancer sites in the body.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Performed by highly trained medical professionals in an outpatient setting, so there is no need of hospital stays for recovery.
Envita's CIPI™: Checked
Standard Surgery: Unchecked

*Individual results may vary. Envita makes no guarantees for outcomes.

Learn more about CIPI™

Types of Cancers of the Gastrointestinal Tract

Colorectal cancers (includes colon and rectal cancers) are the most common cancers of the gastrointestinal tract, and they are categorized depending on the type of cells of disease origin. They are sub-divided as follows:

  • Adenocarcinomas
  • Carcinoid tumors
  • Gastrointestinal stromal tumors
  • Lymphomas
  • Sarcomas

Some of the less common cancers of the gastrointestinal tracts are:

  • Intestinal cancers called the small intestine cancer or small bowel cancer
  • Anal cancer

Call Us Today

At Envita, we have several options for our patients through multifaceted integrated treatment protocols, aiming towards their holistic recovery. Our medical experts, including oncologists, interventional radiologists, researchers, and pharmacists, undergo over 1,500 hours of training to adapt to our unique personalized precision oncology options. If you or a loved one has any questions regarding colon cancer or any other cancer, please contact us at: 866-830-4576. May God bless you on your journey to healing.

References

[1] Zare-Bandamiri M, Fararouei M, Zohourinia S, Daneshi N, Dianatinasab M. Risk Factors Predicting Colorectal Cancer Recurrence Following Initial Treatment: A 5-year Cohort Study. Asian Pac J Cancer Prev. 2017;18(9):2465-2470. Published 2017 Sep 27. doi:10.22034/APJCP.2017.18.9.2465

[2] Hu Z, Ding J, Ma Z, et al. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 2019;51(7):1113-1122. doi:10.1038/s41588-019-0423-x

[3] Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191-197. doi:10.1055/s-0029-1242458

[4] Precision Oncology News, Survey of Precision Oncology Programs Shows Continued Adoption, Though 'Success' Metrics Unclear Nov 04, 2020

[5] Hu T, Li Z, Gao CY, Cho CH. Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol. 2016;22(30):6876-6889. doi:10.3748/wjg.v22.i30.6876

[6] Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138(6):2044-2058. doi:10.1053/j.gastro.2010.01.054

[7] Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology. 2015;148(6):1244-60.e16. doi:10.1053/j.gastro.2014.12.035

[8] Smith, A. , Oertle, J. and Prato, D. (2015) Genetically Targeted Fractionated Chemotherapy. Journal of Cancer Therapy, 6, 182-198. doi: 10.4236/jct.2015.62021.

Choose Envita Medical Centers

Our team is ready to help you get your life back! Please enter your contact information and a Patient Care Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576 .

Please fill out your first name.
Please fill out your last name.
Please fill out your phone number.
Please fill out your email address.
Please make a selection.
Please make a selection.
You may request a call back from 8am-5pm Pacific Time. We cannot guarantee that you will receive a callback during your requested time, but we will do our best to contact you as soon as possible.
Please make a selection.
Please make a selection.
Please make a selection.
Max. 1000 characters. Do not include any web urls.
Please fill out your inquiry.